Project: Sensitive Screening in Treatment of Skin Cancer

We will improve companion diagnostics and monitoring of acquired drug resistance of malignant melanoma (MM) patients, ensuring better response to treatment and reducing use of inefficient therapies. This will be accomplished using our proprietary DNA platform, product development and clinical experiences. The resulting CE certified products will be included in a workflow with a DNA extraction platform and co-marketed by large biotech Promega and tested by end-users on >300 patient samples.

Acronym	SensiScreen Skin (Reference Number: 10440)
Duration	01/10/2016 - 01/10/2019
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 5

Project partner

Number	Name	Role	Country
24071	PentaBase	Coordinator	Denmark
24072	Danish Technological Institute	Partner	Denmark
24073	Istituto Cantonale di Patologia	Partner	Switzerland